Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
181
-
Total 13F shares, excl. options
-
77.7M
-
Shares change
-
-4.2M
-
Total reported value, excl. options
-
$891M
-
Value change
-
-$146M
-
Put/Call ratio
-
0.59
-
Number of buys
-
102
-
Number of sells
-
-91
-
Price
-
$11.47
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q3 2023
255 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2023.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 181 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 77.7M shares
of 105M outstanding shares and own 74.23% of the company stock.
Largest 10 shareholders include Capital World Investors (12M shares), BlackRock Inc. (6.76M shares), Palo Alto Investors LP (5.23M shares), VANGUARD GROUP INC (4.79M shares), JPMORGAN CHASE & CO (4.63M shares), Polar Capital Holdings Plc (4.16M shares), FRANKLIN RESOURCES INC (4.04M shares), Invesco Ltd. (2.9M shares), STATE STREET CORP (2.33M shares), and FMR LLC (1.89M shares).
This table shows the top 181 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.